bosentan anhydrous has been researched along with Hepatorenal Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deray, G; Izzedine, H; Kheder-Elfekih, R; Thabut, D | 1 |
| Baumelou, A; Izzedine, H | 1 |
| Anand, R; Dashwood, M; Goodier, D; Harry, D; Holt, S; Jarmulowicz, M; Milner, P; Moore, K | 1 |
3 other study(ies) available for bosentan anhydrous and Hepatorenal Syndrome
| Article | Year |
|---|---|
Endothelin-receptor antagonist/N-acetylcysteine combination in type 1 hepatorenal syndrome.
Topics: Acetylcysteine; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Free Radical Scavengers; Hepatorenal Syndrome; Humans; Male; Middle Aged; Sulfonamides; Treatment Outcome | 2009 |
Renal failure in cirrhosis.
Topics: Bosentan; Endothelin Receptor Antagonists; Endothelins; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Pyridines; Renal Insufficiency; Sulfonamides; Tetrazoles | 2010 |
Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure.
Topics: Acute Disease; Analysis of Variance; Animals; Antihypertensive Agents; Biomarkers; Bosentan; Cells, Cultured; Endothelin Receptor Antagonists; Endothelin-1; Galactosamine; Hepatorenal Syndrome; Male; Microscopy, Electron; Osmolar Concentration; Rats; Rats, Sprague-Dawley; Renal Circulation; Statistics, Nonparametric; Sulfonamides; Up-Regulation | 2002 |